Why Are We Failing to Implement Imaging Studies with Radiolabelled New Molecular Entities in Early Oncology Drug Development?

Table 1

Examples of some the clinical PET biodistribution studies performed with radiolabelled anticancer agents.

Drug	References
5-Fluorouracil	[10, 11]
Temozolomide	[12, 13]
N-[(2′-dimethylamino)ethyl]acridine-4-carboxamide (XR5000)	[14, 15]
Antisense oligonucleotide to Survivin (LY2181308)	[16, 17]
Docetaxel	[18]
Paclitaxel	[19]
Lapatinib	[20]
Erlotinib	[21–23]
Anti-CD44v6 chimeric monoclonal antibody, U36	[24]
Trastuzumab	[25, 26]
Some radiolabelled molecular entities under evaluation in ongoing imaging studies (NIH trial database)
^89Zr-Bevacizumab, ^89Zr-RO5323441 (placental growth factor antibody), ^18F-SKI-249380 (dasatinib derivative), ^124I-PUH71, MMOT0530A (a monoclonal antibody), ^18F-Paclitaxel, ^11C-Erlotinib, and ^89Zr-Cetuximab